Blood Levels of Glutamine and Nitrotyrosine in Patients with Chronic Viral Hepatitis

References

• Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509–523. doi:10.1038/nri.2016.69
   PubMed Web of Science ®Google Scholar
• Yadav D, Hertan HI, Schweitzer P, Norkus E, Pitchumoni C. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97(10):2634–2639. doi:10.1111/j.1572-0241.2002.06041.x
   PubMed Web of Science ®Google Scholar
• Amores-Sánchez MI, Medina MÁ. Glutamine, as a precursor of glutathione, and oxidative stress. Mol Genet Metab. 1999;67(2):100–105. doi:10.1006/mgme.1999.2857
   PubMed Web of Science ®Google Scholar
• Tsai PH, Liu JJ, Yeh CL, Chiu WC, Yeh SL. Effects of glutamine supplementation on oxidative stress-related gene expression and antioxidant properties in rats with streptozotocin-induced type 2 diabetes. Br J Nutr. 2012;107(8):1112–1118. doi:10.1017/S0007114511004168
   PubMed Web of Science ®Google Scholar
• Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10(11):1564. doi:10.3390/nu10111564
   PubMed Web of Science ®Google Scholar
• Rao KVR, Jayakumar AR, Norenberg MD. Glutamine in the pathogenesis of acute hepatic encephalopathy. Neurochem Int. 2012;61(4):575–580. doi:10.1016/j.neuint.2012.01.012
   PubMed Web of Science ®Google Scholar
• Rama Rao KV, Norenberg MD. Glutamine in the pathogenesis of hepatic encephalopathy: the trojan horse hypothesis revisited. Neurochem Res. 2014;39(3):593–598. doi:10.1007/s11064-012-0955-2
   PubMed Web of Science ®Google Scholar
• Helling G, Wahlin S, Smedberg M, et al. Plasma glutamine concentrations in liver failure. PLoS One. 2016;11(3):e0150440. doi:10.1371/journal.pone.0150440
   PubMed Web of Science ®Google Scholar
• Rodas PC, Rooyackers O, Hebert C, Norberg Å, Wernerman J. Glutamine and glutathione at ICU admission in relation to outcome. Clin Sci. 2012;122(12):591–597. doi:10.1042/CS20110520
   Web of Science ®Google Scholar
• García-Monzón C, Majano PL, Zubia I, Sanz P, Apolinario A, Moreno-Otero R. Intrahepatic accumulation of nitrotyrosine in chronic viral hepatitis is associated with histological severity of liver disease. J Hepatol. 2000;32(2):331–338. doi:10.1016/S0168-8278(00)80080-X
   PubMed Web of Science ®Google Scholar
• Calderón‑Torres CM, Sarabia‑Curz L, Ledesma‑Soto Y, Murguía‑Romero M, Terrazas LI. Denitrase activity of Debaryomyces hansenii reduces the oxidized compound 3‑nitrotyrosine in mice liver with colitis. Exp Ther Med. 2019;17(5):3748–3754.
   PubMed Web of Science ®Google Scholar
• Meng L, Gao A, Bian J, Han L, Chen H. Study on correlation between oxidation-antioxidation and chronic hepatitis viral B. Occup Health. 2010;23. Available from: https://en.cnki.com.cn/Article_en/CJFDTotal-ZYJK201023095.htm.
   Google Scholar
• Alavian SM, Showraki A. Hepatitis B and its relationship with oxidative stress. Hepat Mon. 2016;16(9):e37973. doi:10.5812/hepatmon.37973
   PubMed Web of Science ®Google Scholar
• Namiduru ES, Namiduru M, Tarakçioğlu M, Tanriverdi M. Levels of malondialdehyde, myeloperoxidase and nitrotyrosine in patients with chronic viral hepatitis B and C. Adv Clin Exp Med. 2012;21(1):47–53.
   PubMed Web of Science ®Google Scholar
• De Matteis C, Cariello M, Graziano G, et al. AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects. Sci Rep. 2021;11(1):14834. doi:10.1038/s41598-021-94277-3
   PubMed Web of Science ®Google Scholar
• Montoliu C, Cauli O, Urios A, et al. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol. 2011;106(9):1629. doi:10.1038/ajg.2011.123
   PubMed Web of Science ®Google Scholar
• Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–1316. doi:10.1097/JTO.0b013e3181ec173d
   PubMed Web of Science ®Google Scholar
• Kanyongo GY. The influence of reliability on four rules for determining the number of components to retain. J Mod Appl Stat Methods. 2005;5(2):7. doi:10.22237/jmasm/1162353960
   Google Scholar
• Leach LF, Henson RK. Bias and precision of the squared canonical correlation coefficient under nonnormal data condition. J Mod Appl Stat Methods. 2014;13(1):8. doi:10.22237/jmasm/1398917220
   Google Scholar
• Tominaga T, Suzuki H, Mizuno H, et al. Clinical significance of measuring plasma concentrations of glutamine and glutamate in alcoholic liver diseases. Alcohol Alcohol. 1993;28(Supplement_1A):103–109. doi:10.1093/alcalc/28.Supplement_1A.103
   Web of Science ®Google Scholar
• Ivanov AV, Valuev-Elliston VT, Tyurina DA, et al. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget. 2017;8(3):3895–3932. doi:10.18632/oncotarget.13904
   PubMedGoogle Scholar
• Lévy PL, Duponchel S, Eischeid H, et al. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology. 2017;65(3):789–803. doi:10.1002/hep.28949
   PubMed Web of Science ®Google Scholar
• Bard-Chapeau EA, Nguyen AT, Rust AG, et al. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet. 2014;46(1):24–32. doi:10.1038/ng.2847
   PubMed Web of Science ®Google Scholar
• Kuramitsu Y, Harada T, Takashima M, et al. Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus. Electrophoresis. 2006;27(8):1651–1658. doi:10.1002/elps.200500718
   PubMed Web of Science ®Google Scholar
• Long J, Wang H, Lang Z, Wang T, Long M, Wang B. Expression level of glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis and chronic hepatitis B. Hepatol Int. 2011;5(2):698–706. doi:10.1007/s12072-010-9230-2
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Godlewska B, Near J, et al. Effect of interferon-α on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. Psychol Med. 2014;44(4):789–795. doi:10.1017/S0033291713001062
   PubMed Web of Science ®Google Scholar
• Smedberg M, Wernerman J. Is the glutamine story over? Crit Care. 2016;20(1):361. doi:10.1186/s13054-016-1531-y
   PubMed Web of Science ®Google Scholar
• Melis GC, Ter Wengel N, Boelens PG, van Leeuwen PA. Glutamine: recent developments in research on the clinical significance of glutamine. Curr Opin Clin Nutr Metab Care. 2004;7(1):59–70. doi:10.1097/00075197-200401000-00011
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Shimizu K, Hata N, et al. Both high and low plasma glutamine levels predict mortality in critically ill patients. Surg Today. 2017;47(11):1331–1338. doi:10.1007/s00595-017-1511-0
   PubMed Web of Science ®Google Scholar
• Lemberg A, Fernández MA. Hepatic encephalopathy, ammonia, glutamate, glutamine and oxidative stress. Ann Hepatol. 2009;8(2):95–102. doi:10.1016/S1665-2681(19)31785-5
   PubMed Web of Science ®Google Scholar
• Jin H, Wang S, Zaal EA, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. eLife. 2020;9. doi:10.7554/eLife.56749
   Web of Science ®Google Scholar
• Mondello S, Galuppo M, Mazzon E, et al. Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. Eur J Pharmacol. 2010;643(2–3):304–315. doi:10.1016/j.ejphar.2010.06.044
   PubMed Web of Science ®Google Scholar
• Marques C, Licks F, Zattoni I, et al. Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy. World J Gastroenterol. 2013;19(28):4464–4474. doi:10.3748/wjg.v19.i28.4464
   PubMed Web of Science ®Google Scholar
• Bandookwala M, Sengupta P. 3-Nitrotyrosine: a versatile oxidative stress biomarker for major neurodegenerative diseases. Int J Neurosci. 2020;130(10):1047–1062. doi:10.1080/00207454.2020.1713776
   PubMed Web of Science ®Google Scholar
• Sanz-Cameno P, Medina J, García-Buey L, et al. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol. 2002;37(6):723–729. doi:10.1016/S0168-8278(02)00266-0
   PubMed Web of Science ®Google Scholar
• Kim JH, Moon HW, Ko SY, Choe WH, Kwon SY. Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-Adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol. 2014;20(3):274–282. doi:10.3350/cmh.2014.20.3.274
   PubMedGoogle Scholar
• Fu XY, Tan DM, Liu CM, et al. Early hepatitis B viral DNA clearance predicts treatment response at week 96. World J Gastroenterol. 2017;23(16):2978–2986. doi:10.3748/wjg.v23.i16.2978
   PubMed Web of Science ®Google Scholar
• Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis. 2015;60(12):1743–1751. doi:10.1093/cid/civ170
   PubMed Web of Science ®Google Scholar